Golidocitinib Elicits Durable Responses in Relapsed/Refracto

Golidocitinib can produce lasting responses in patients with relapsed or refractory PTCL, according to a new study. Golidocitinib can produce lasting responses in patients with relapsed or refractory PTCL, according to a new study.

Related Keywords

Peking , Beijing , China , Yuqin , Xizang , , University Cancer Hospital , Yuqin Song , Peking University Cancer Hospital ,